Literature DB >> 50879

Tumor immunoprophylaxis in mice using glutaraldehyde-treated syngeneic tumor cells.

P Frost, C J Sanderson.   

Abstract

The ability of glutaraldehyde-treated tumor cells to induce protection against subsequent challenge has been studied in a syngeneic system. Two tumors have been tested in BALB/c mice. The first was a methylcholanthrene-induced tumor that has been maintained in serial passage for over a decade. The second was a spontaneous mammary adenoacanthoma that was tested at the third passage. The protection was found to consist of two components: (a) a specific immunological component; and (b) a nonspecific component observed when the immunizing and challenge dose were both given i.p. This nonspecificity, while possibly an element in tumor protective mechanisms, may confuse careful analytical studies of the immunogenic potential of tumor antigens.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 50879

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Protection against Marek's disease-derived tumor transplants by the nononcogenic SB-1 strain of Marek's disease virus.

Authors:  K A Schat; B W Calnek
Journal:  Infect Immun       Date:  1978-10       Impact factor: 3.441

2.  The effect of purification on the immunogenicity of tumor-specific transplantation antigens.

Authors:  T L Saunders; B D Kahan; N R Pellis
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

3.  Selection of cytotoxic T-cell precursors specific for minor histocompatibility determinants. I. Negative selection across H-2 barriers induced with disrupted cells but not with glutaraldehyde-treated cells: evidence for antigen processing.

Authors:  R Korngold; J Sprent
Journal:  J Exp Med       Date:  1980-02-01       Impact factor: 14.307

4.  Tumour immunoprophylaxis in mice using glutaraldehyde-treated syngeneic myeloma cells.

Authors:  S Ben-Efraim; R Ophir; E H Relyveld
Journal:  Br J Cancer       Date:  1981-04       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.